Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
9,448 total articles
Viking Therapeutics (VKTX) is a clinical-stage biotech with a GLP-1/GIP-weight loss candidate, VK2735, edging toward a commercial inflection. With the stock trading around $30.75 after a volatile session, elevated short interest and above-average volume suggest institution-level accumulation. This trade idea lays out an entry at $30.75, a stop at $…
MP Materials (MP) is trading well off its 52-week high after a pullback in rare-earth sentiment. The company has a tangible government cushion - a $400M DoD investment and a 10-year magnet supply agreement with a $110/kg price floor - that provides a policy-backed cash-flow floor. This trade targets a recovery toward $85 driven by contract-driven r…
MSCI announced a 13.9% dividend increase with ex-dividend on 02/13/2026 while continuing to deliver double-digit revenue and EPS growth. The stock is trading near $522 with technicals showing short-term oversold conditions; we outline a mid-term swing trade that captures upside to $600 while limiting downside with a $490 stop.
Microsoft's mix of cloud scale, strong free cash flow and favorable AI positioning make it an attractive buy after a pullback tied to headlines around OpenAI's valuation. The company trades at ~25x earnings with $77B of free cash flow and a $2.98T market cap. Technicals look oversold while macro AI capex remains a tailwind. Trade plan included for …
Tuya is a rare combination in the small-cap tech bucket: reported profitability (P/E ~27), platform-scale AI interactions, and a market cap of roughly $1.34B. The market prices the stock like a cyclical IoT vendor; we see a reasonable asymmetric upside over the next 45 trading days if product monetization and adoption signals continue to improve.
Crocs reported a solid Q4 and remains underappreciated by the market. At roughly $98.46, the stock trades at about a $5.1B market cap with free cash flow of $716M, implying a FCF yield in the low double-digits and an EV/EBITDA of ~6.2. That combination of strong cash conversion, brand strength, and buyback optionality makes CROX an actionable long …
Gray Media owns the largest portfolio of local TV stations in the U.S., and its expanding Spanish-language footprint plus upcoming sports and political programming create a clear revenue lever for 2026. Valuation metrics look cheap at the equity level, but leverage is high. This trade targets a re-rating into the mid-$6s as political and sports ad …
REGENXBIO (RGNX) is a clinical-stage AAV gene therapy company that traded lower after the FDA placed clinical holds on RGX-111 and RGX-121 following a reported neoplasm case. At $8.33 and a market cap near $422M, the stock appears to price in meaningful program risk. I am cautiously bullish: enter a staged long with tight risk control and a target …
Macro conditions and risk-asset flows argue for buying Bitcoin on this pullback. With markets pricing a very high chance of unchanged Fed policy in March and risk assets showing early signs of rotation into AI and growth, this trade seeks to capture a rebound from what looks like an oversold leg. Strict risk controls and a clear stop make this a dr…
Innovative Solutions & Support reported continuing double-digit growth driven by F-16 product integration and aftermarket demand. Market reaction has been muted by timing effects and legal headlines, creating a tradeable pullback. I lay out a mid-term swing entry, stop and target with the rationale, catalysts and balanced risk framing.
Euronext looks buyable ahead of its upcoming results. Structural revenue streams from listings, trading and market data, combined with visible listing activity and management share purchases across European listings, create a favorable setup. Enter at $90.00 with a $82.00 stop and $105.00 target over a mid-term (45 trading days) horizon.
Chipotle (CMG) looks neither deeply undervalued nor richly expensive. The shares trade near $35.84 with a ~30-31x P/E and strong return metrics, but 2025 traffic weakness and margin trade-offs in 2026 mean upside depends on re-accelerating visits. A measured, mid-term buy-on-weakness approach with a defined stop and target captures upside if traffi…
Neurocrine (NBIX) sold off after below-expectation Ingrezza guidance, but the underlying business remains healthy: Ingrezza grew to $2.51B, Q4 sales topped $805.5M, and the company generates meaningful free cash flow. This trade idea buys the weakness with a clear stop and a 180-trading-day target that prices in recovery plus pipeline upside.
Illinois Tool Works (ITW) looks set to outpace the market as automotive and industrial demand normalizes and the company extracts more operating leverage from restructuring and pricing. Valuation is not cheap, but free cash flow generation, a 2%+ dividend, and strong ROE support a disciplined long trade with a clear stop and target.
Sana (SANA) is a speculative long setup that pays to be small and patient. The company’s fusogen in vivo gene-editing work (published in Nature Biotechnology) is a real scientific milestone; the stock is cheap relative to upside if that program wins, but Sana faces cash burn, prior dilution and active litigation. Trade size accordingly and use a ha…
Eos Energy is a high-volatility battery-storage stock that has re-rated on early commercial traction and a large project pipeline. Technicals show the stock pulling back toward support after a big run; the trade targets a breakout to $15 over the next 45 trading days while limiting downside with a $9 stop.
Atlanta Braves Holdings (BATRA) sits at a premium valuation with negative free cash flow and meaningful leverage. Recent options flow and Liberty-related restructuring chatter raise the odds management tests a direct-to-consumer or new local-media approach. If that happens, the company could face higher capex, rights costs, and margin pressure — an…
Norwegian Cruise Line (NCLH) offers a mid-term swing trade setup. Shares are discounted relative to peers, technical momentum is constructive and booking momentum from wave season should flow into revenue and pricing. We lay out an entry at $23.00, stop at $20.00 and a target of $28.00 over a 45 trading-day horizon, with clear triggers that would c…
UniCredit looks like a high-quality European bank whose recent return-on-equity and margin resilience justify paying up relative to peers. With higher-for-longer rates, continued NPL clean-up and management discipline, the stock is a buy for investors willing to hold through macro volatility. This trade idea lays out exact entry, stop and target le…
WEX Inc. looks materially undervalued on cash flow and earnings multiples relative to its growth profile, but recent revenue softness, activist pressure and execution gaps in Mobility and Corporate Payments mean this is a trade, not a buy-and-forget. Enter a measured long at current levels with a firm stop and a target near the 52-week high - a mid…
Targa Resources (TRGP) is priced as a mature midstream owner but is funding a multi-billion dollar Permian buildout that should expand EBITDA and free cash flow over the next 12-18 months. With dividend increases, debt refinancing completed, and a clear pipeline of growth projects, the risk/reward favors loading a position now. This trade outlines …
Amazon has been hit hard in a broad tech selloff driven by AI capex fears. The drop has pushed technical indicators into deeply oversold territory while AWS growth and large-scale AI investment provide a clear fundamental runway. This trade idea lays out an actionable mid-term plan with entry, stop and target, and a balanced view of risks and catal…
Affirm has moved beyond promise to proof: GAAP profitability, accelerating gross merchandise volume, material free cash flow, and strategic partnerships create a clear path for margin expansion. The market's knee-jerk sell-off to $49.86 creates an actionable entry for a long position targeting a re-rating back toward growth multiple peers, with def…
FDA approval of Optune Pax for locally advanced pancreatic cancer materially broadens NovoCure's TAM and gives the stock a near-term re-rating lever. The catalyst is clear; the trade is to buy a measured entry on the post-announcement pullback with defined stop and target.
Arhaus has pulled back to $9.13 after a bout of selling that looks more technical than structural. The business is cash-generative, lightly levered, and expanding showrooms while raising revenue guidance in recent quarters. At roughly $1.29B market cap and a P/S near 1.0, this is a buy-the-dip setup with a clear entry, stop, and target for a mid-te…
